Kozni ambulance Kutna Hora s.r.o. — Clinical Trial Site

9 Registered trials

3 Currently recruiting

Organisation

Kozni ambulance Kutna Hora s.r.o.

Location

Hlouska, Czechia

Identifier

ORG-100045332

Address

Kpt. Vosky 781, Hlouska, 284 01, Czechia

Departments

Dermatologie
Dermatology
Dermatovenereology
N/A
NA

Clinical trials at this site (9)

Search interface

An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag… Recruiting

2023-503630-44-00 Treatment of moderate-to-severe Atopic dermatitis 10 2024-11-20
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended

2023-509425-53-00 Atopic Dermatitis 5 2015-11-09
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl… Ended

2023-507193-40-00 Moderate to Severe Plaque Psoriasis 5 2025-01-16
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap… Ended

2022-502653-34-01 Atopic dermatitis and moderate-to severe atopic hand ec 11 2024-05-30
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2023-506557-38-00 Dermatitis atopic 5 2024-05-16
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15